Gadeta B V Based In Utrechtnetherlandsis A Biotechnology Company Founded In 2015 That Specializes In Gamma Delta T Cell Receptortcrbased Immunotherapies For Cancer Treatmentrecently Acquired By Clade Therapeutics In October 2023Gadeta Has Raised $7 8 Million In Funding Prior To The Acquisitionthe Company Collaborates With Kite Pharma To Advance Its Gamma Delta Tcr Technology For Solid Tumors Gadeta Utilizes Its Proprietary Combinatorial T Cell Receptor Exchangecteplatform To Develop Engineered T Cell Therapiesits Lead Investigational Productst Cells Engineered To Express A Defined Gamma Delta Tcrtegs Target Solid Tumors And Hematological Malignanciesthe Company Holds 11 Patents Related To Gamma Delta Tcr Based Cancer Therapiesincluding A Key Patent Granted In June 2023Gadeta S Innovative Approach Aims To Enhance T Cell Persistence And Target Diverse Tumor Antigensaddressing Limitations Of Conventional Car T Therapies
